

2021 #33

September 17, 2021

INSIDE:

BRIEFLY NOTED 2
 RESEARCH IN BRIEF 3
 WORD IN WASHINGTON
 3
 INFECTIOUS DISEASES
 UPDATE..... 4
 Upcoming ABC Webinars
 – Don't Miss Out! 4
 ABC Webinar: UK's
 Transition to an
 Individual Donor Risk
 Assessment..... 5
 Save The Date for the 60th
 ABC Annual Meeting.... 5
 Results Available from
 ABC 2021 Workplace
 Violence Risk Reduction
 Survey 5
 ADRP Partners with Sickle
 Cell Disease Association
 of America 6
 NEW on CollABORate 6
 MEMBER NEWS 6
 COMPANY NEWS..... 7
 CALENDAR..... 8
 POSITIONS..... 9

FDA Announces November BPAC Meeting

The U.S. Food and Drug Administration announced that the Blood Products Advisory Committee (BPAC) will hold its next meeting online on November 4th from 9:30 a.m. – 5:20 p.m. ET. Topics to be discussed by the committee include:

- an overview of the research programs of the Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER);
- an overview of the research programs of the Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review (OBRR), CBER; [and]
- an overview of the research programs of the Laboratory of Emerging Pathogens, Division of Emerging & Transfusion Transmitted Diseases, OBRR, CBER.

Individuals can join an online [webcast](#) to view the portions of the meeting open to the public. According to the announcement, all meeting materials will be made available to the public no later than two business days prior to the meeting. “Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before October 28th.”

(Source: FDA Announcement, 9/13/21) ♦

CDC Updates Interim Infection Prevention and Control Recommendations for Healthcare Personnel During COVID-19 Pandemic

The Centers for Disease Control and Prevention (CDC) [published](#) changes to its “Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.” According to the agency, “[t]his guidance applies to all U.S. settings where healthcare is delivered, including home health.” The updates include:

- [u]pdated source control recommendations to address limited situations for healthcare facilities in counties with low to moderate community transmission where select fully vaccinated individuals could choose not to wear source control. However, in general, the safest practice is for everyone in a healthcare setting to wear source control;

(continued on page 2)

CDC Recommendations (continued from page 1)

- [u]pdated quarantine recommendations for fully vaccinated patients who have had close contact with someone with SARS-CoV-2 infection to more closely align with recommendations for the community;
- [c]larified the recommended intervals for testing asymptomatic HCP with a higher-risk exposure and patients with close contact with someone with SARS-CoV-2 infection; [and]
- [a]dded content from previously posted CDC guidance addressing:
 - [r]ecommendations for fully vaccinated HCP, patients, and visitors;
 - SARS=CoV-2 testing;
 - Duration of Transmission-Based Precautions for patients with SARS-CoV-2 infection; [and]
 - [s]pecialized healthcare settings (e.g., dental, dialysis, EMS).

(Source: CDC [Announcement](#), 9/10/21) 💧

BRIEFLY NOTED

The U.S. Food and Drug Administration [published](#) a revised guidance titled “Enforcement Policy for Face Masks, Barrier Face Coverings, Face Shields, Surgical Masks, and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency.” The revisions aim to “to help expand the availability of face masks, barrier face coverings, and face shields for the general public, including health care personnel, and surgical masks and particulate filtering facepiece respirators (FFRs) (including N95 respirators) for health care personnel for the duration of the COVID-19 public health emergency.”

This guidance is unlikely to impact blood centers. The original version outlined options for alternative face coverings when personal protective equipment (PPE) shortages were occurring, and PPE could not be obtained. The guidance has been updated to reflect the fact that such shortages are no longer a concern.

(Source: FDA [Guidance](#), 9/15/21) 💧

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2021 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry
Chief Medical Officer: Rita Reik
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to memberservices@americasblood.org
America’s Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.



RESEARCH IN BRIEF

Preparing for Blood Shortages, The Canadian Experience - First Six Months of COVID-19. Authors of a paper in *Transfusion* discuss “the Canadian National Plan for Shortages of Labile Blood Components (the Plan) [that was developed] in 2009...The Plan [had] the potential to convene the National Emergency Blood Management Committee (NEBMC), a congress of approximately 50 people...In times of blood inventory constraint, the NEBMC determines if the declaration of an inventory shortage phase is required [Green to Red and Recovery], recommends actions necessary to mitigate inventory challenges, and coordinates communications to be disseminated to hospital laboratory and clinical stakeholders. The Plan provides a framework for blood supply management during a nationwide shortage to ensure a consistent and collaborative mechanism through coordinated, open discussion.” The authors explained that “[i]n the days following the declaration of COVID-19 as a global pandemic on March 11, 2020, all Canadian provinces declared states of emergency, which led to business closures and population-wide sheltering in-place...On March 16, 2020, the NEBMC met to discuss concerns about the security of Canada’s national blood supply...[They] met weekly (for 3 months) to maintain a framework for effective coordination, consensus building, common messaging, and rapid decision-making during this sustained period of demand and supply volatility.” They noted that “hospital transfusion services began aggressively promoting restrictive transfusion practices or the use of alternatives to transfusion to minimize the anticipated negative impact on blood inventory related to the rapid decline in donations and collections.” “[Canadian Blood Services] initially experienced a reduction in its planned mobile collection sites to approximately 33 percent of its collection capacity during March...[This] was offset by a significantly greater reduction in demand than had been expected to a nadir of 36 percent before beginning to recover in early April...On July 14, 2020, the NEBMC notified hospitals of the transition to Green Phase (normal inventory operations).” The authors concluded that a “careful analysis of blood component utilization trends by CBS and a review of actions within provincial and hospital jurisdictions will inform revisions to the Plan, including the addition of a specific section on pandemic planning to ensure optimization of processes in the future.”

Citation: Prokopchuk-Gauk, O, Petraszko, T, Nahirniak, S, Doncaster, C, Levy, I. [Blood shortages planning in Canada: The National Emergency Blood Management Committee experience during the first 6 months of the COVID-19 pandemic.](#) *Transfusion.* 2021.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

WORD IN WASHINGTON

The U.S. Food and Drug Administration (FDA) has [revised](#) the emergency use authorization (EUA) for bamlanivimab and etesevimab administered together to treat COVID-19. The revision authorizes the monoclonal antibodies “for use after exposure to the virus and are not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus. Health care providers should review the [fact sheet](#) for detailed information about use of this therapy for post-exposure prophylaxis...Post-exposure prophylaxis as authorized with bamlanivimab and etesevimab, administered together, is not a substitute for vaccination against COVID-19. FDA has approved one vaccine and authorized others to prevent COVID-19 and serious clinical outcomes caused by COVID-19, including hospitalization and death. FDA urges you to get vaccinated if you are eligible. Learn more about FDA-approved or -authorized COVID-19 vaccines.”

(Source: FDA [Announcement](#), 9/16/21)

FDA announced this week the [creation](#) of a new office of digital transformation. The Office of Digital Transformation (ODT) is part of a “reorganization of the agency’s information technology (IT), data management and cybersecurity functions...This reorganization will advance the agency’s information

(continued on page 4)

WORD IN WASHINGTON (continued from page 3)

technology transformation with improved data and IT competencies that improve agency operations to support the public health mission. The reorganization is a significant step in the FDA’s technology and data modernization efforts that began more than two years ago. The reorganization allows the FDA to bring more effective and efficient data and IT management, built on best practices, to streamline and advance FDA operations by reducing duplicative processes, implementing technological efficiencies using projects that deliver the most customer benefits, and promoting shared services within agency offices and centers to strategically and securely further the agency’s regulatory mission...The FDA FY 2022 budget request included funding to support the agency’s data and IT modernization efforts for enterprise-wide data modernization.”

(Source: FDA [Announcement](#), 9/15/21) ♦

INFECTIOUS DISEASES UPDATE**EBOLA**

Johnson & Johnson [announced](#) that two papers published in *The Lancet Infectious Diseases* reported that the company’s investigational Ebola vaccine regimen “generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with immune responses persisting in adults for at least two years.” According to a company news release, “these findings support the potential prophylactic use of the vaccine regimen...The data is from the Phase 3 EBOVAC-Salone clinical study and showed that the vaccine regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98 percent of all participants. There were no safety signals of concern...The EBOVAC-Salone study was conducted in Sierra Leone and is the first to assess the safety and tolerability of the Johnson & Johnson Ebola vaccine regimen in adults in a region affected by the 2014-2016 West African Ebola outbreak, which was the worst on record.”

(Source: Johnson & Johnson [News Release](#), 9/13/21) ♦

Upcoming ABC Webinars – Don’t Miss Out!

- **United Kingdom’s Transition to an Individual Risk Assessment** – Sept. 21st from 12 – 1 p.m. (EDT). Login information available to ABC members [here](#).
- **ABC SMT Journal Club Webinar** – Dec. 13th. More details coming soon.

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ABC Webinar: UK's Transition to an Individual Donor Risk Assessment

America's Blood Centers (ABC) invites member blood centers to a webinar on September 21st at noon EDT to learn about the "United Kingdom's (UK) Transition to an Individual Donor Risk Assessment." With the [ADVANCE study](#) currently ongoing in the U.S., the UK approach can provide valuable insights on the move to a more inclusive donor eligibility process and its potential impact on the donor base. In June 2021, the UK implemented new eligibility requirements based on a more individualized assessment rather than on a risk assigned to a group or population. Under the new donor eligibility process, any individual who wishes to give blood, regardless of gender, will be asked about recent sexual activity. This webinar will feature:

- Dr. Su Brailsford, a consultant in Epidemiology and Health Protection and interim associate medical director for Microbiology/IPC/Legal at NHS Blood and Transplant (NHSBT). Dr. Brailsford leads the joint NHSBT/Public Health England Epidemiology Unit and has been involved in the previous assessments of men who have sex with other men (MSM) and blood donation in 2010 and 2016; and
- Katy Davison is an epidemiologist at Public Health England working with Dr. Brailsford's joint team. She was also involved in the previous assessments of MSM and blood donation and is deputy chair of the FAIR ([For the Assessment of Individualized Risk](#)) steering group.

Login information to join the webinar is available to ABC members in MCN 21-076. Please contact [ABC Member Services](#) to receive a copy of the MCN.

Save The Date for the 60th ABC Annual Meeting

Mark your calendars for the [60th ABC Annual Meeting](#) and 25th Annual *Awards of Excellence*. These events will take place March 7th-9th at the Ritz-Carlton (Pentagon City) in Arlington, V.A. Please secure your hotel [reservation](#) today. This year's meeting will be in-person while Advocacy Day will be held virtually the following week given continued visitor restrictions on Capitol Hill. This will allow each blood center to bring together multiple colleagues to connect with their members of Congress and their staff. More information will be provided to ABC members as it becomes available. The ABC Annual Meeting brings together blood center executives and national leaders to discuss advocacy and regulatory updates, the latest in science, medicine, and technical affairs, and hot topics facing the blood community. In addition, ABC is excited to share that the final day of this year's meeting will feature two in-depth training workshops focused on building tangible advocacy skills that can immediately benefit your center. Topics will be released when registration opens. Please contact [ABC Member Services](#) with questions.

Results Available from ABC 2021 Workplace Violence Risk Reduction Survey

ABC has published the results of the ABC 2021 Workplace Violence Risk Reduction Survey. It was developed jointly by ABC and BCx, a reciprocal insurance company owned and operated by blood centers, for members regarding security initiatives and activities at blood centers. Knowing the industry standards for

(continued on page 6)



INSIDE ABC (continued from page 5)

security helps blood centers in assessing their workplaces. Members can find the data in MCN 21-074. Please contact ABC Director of Quality Services [Toni Mattoch](#) to receive the data or a copy of the MCN.

ADRP Partners with Sickle Cell Disease Association of America

With National Sickle Cell Awareness Month beginning September 1st, ADRP, an international division of ABC, is announcing a partnership with the Sickle Cell Disease Association of America. To raise awareness of the need for blood donations from a diverse group of donors to help treat individuals with sickle cell disease, the two organizations have created social media [graphics](#) and a [video](#). Blood centers are encouraged to use these resources and designated hashtags (#sicklecellmatters2021, #sicklecellawarenessmonth, #SCDSCTMatters, and #SickleCell) throughout the month of September. ♦

NEW on CollABOrate

COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABOrate](#) Online Member Community include:

- [The Blood Community Remembers 9/11](#) (ALL MEMBER FORUM)
- [High School Blood Drives](#) (COMMUNICATIONS and DONOR RECRUITMENT)
- [Promising Innovations for Blood Banking and Transfusion Medicine](#) (MEDICAL ISSUES)
- [Onboarding and Training](#) (HUMAN RESOURCES)
- [Product Traceability BB/TS 5.1.6.2](#) (QUALITY BYTES)
- [Washed RBCs](#) (TECHNICAL DIRECTORS)

ABC members are encouraged to [login](#) and join the conversations today!

MEMBER NEWS

Stanford Blood Center has [partnered](#) with The Tech Interactive on the “Give Good” initiative. For each donor that donates from September 13th- 19th, the blood center will make a financial contribution to The Tech Interactive to “support educational programs for youth at the nonprofit science and technology center.” The Tech Interactive will also host an on-site blood drive as a part of the partnership. “Give Good is a wonderful opportunity to help spread the word about blood donation, while giving back to a community organization with a good cause,” said Harpreet Sandhu, MBA, chief executive officer (CEO) at Stanford Blood Center, in a news release. “We’re proud to support STEAM (science, technology, engineering, arts and math) education through The Tech Interactive as they provide local kids with hands-on learning experiences to help them better prepare for the future.” Katrina Stevens, president and CEO at The Tech Interactive, added in the release, “[w]e’re excited to partner once again with Stanford Blood Center to help raise awareness about the importance of blood donation and the impact donors have in helping save lives. It’s thanks to generous contributions like this that help us continue our work to develop the future problem-solvers of tomorrow and offer engaging activities to children to help expand their imagination.”

(Source: Stanford Blood Center [News Release](#), 9/13/21)

(continued on page 7)



MEMBER NEWS (continued from page 6)

Community Blood Bank of Northwest Pennsylvania and Western New York recently honored Ed Althof, by naming an award after him. According to the announcement, Mr. Althof is a 60-gallon donor who has long been a champion of the organization and blood donation in addition to serving on the board of directors at the blood bank. The first Ed Althof Commitment to Community Award was presented to him during a small reception at the blood bank and “each year Community Blood Bank will seek nominations for people who embody this spirit of commitment and caring for others through support of blood donation” to recognize such individuals with this honor. “My story’s not that different from a lot of other dedicated donors’ [stories],” said Mr. Althof in the announcement. “I started when I was in my early 20s. It’s the feeling it gives you inside and the ability to help someone. We don’t know who. All we know is that somebody is in a critical situation somewhere in the region.”



Left: Deanna Renaud Community Blood Bank Executive Director; Right: Ed Althof.

Versiti Blood Center of Ohio announced it will open its first fixed site location in Ohio early next year according to a [report](#) in the *Columbus Business Journal*. “We’ thrilled that early next year we will have a permanent location where donors can drop in and donate blood at their convenience to help save lives,” said Heather Sever, MBA, area vice president and director of Donor Services, in the article. “This fixed location will allow us to serve the patients in need of blood at the Wexner Medical Center at an even higher capacity.” The new center will have 6,300 square feet of office and donor space.

(Source: *Columbus Business Journal*, [Versiti Blood Center of Ohio to open first permanent donor center near Hilliard](#), 9/15/21) ◆

COMPANY NEWS

Terumo Blood and Cell Technologies recently [announced](#) that Health Canada, the country’s regulatory authority, has approved the company’s Mirasol® Pathogen Reduction Technology System for use in treating platelets. “We believe everyone is entitled to a safe, sustainable and adequate blood supply. We work with hospitals, advocacy associations and governments to increase awareness and access to products, like pathogen reduction, that can improve patient outcomes. Now, blood centers in Canada have another option to do just that,” said Michelle Marks, director of Marketing and Blood Center Solutions at Terumo Blood and Cell Technologies in a news release. “We would also like to recognize Canadian Blood Services’ participation in the PREPARES study which was used to support the registration.” Terumo’s PRT system uses “riboflavin (vitamin B2) and ultraviolet light” to reduce pathogens in blood products and is “CE marked for platelets, plasma and whole blood and is in routine use in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America. The system is only for investigational research in the U.S.”

(Source: Terumo Blood and Cell Technologies [News Release](#), 8/18/21)

BloodHub has [reached](#) the milestone of generating 10 million orders since the company’s inception a decade ago according to a recent announcement. “In 2021, we will process more than 2 million orders, equaling

(continued on page 8)



COMPANY NEWS (continued from page 7)

17 million blood components, 200,000+ laboratory orders, and \$1 billion invoiced,” said Michael Pandelakis, founder and chief executive officer at BloodHub, in the announcement. “The BloodHub ecosystem continues to expand its mission-critical role in the nation’s healthcare supply chain.”

(Source: BloodHub [Announcement](#), 9/15/21)

Excision BioTherapeutics, Inc. had an investigational new drug (IND) application [accepted](#) by U.S. Food and Drug Administration (FDA) for the company’s CRISPR-based therapeutic candidate in development as a potential cure for chronic HIV. A phase I/II clinical trial will soon begin “to evaluate the safety, tolerability, and efficacy” of the therapy in individuals living with HIV. The gene therapy is an “*in vivo* CRISPR-based therapeutic designed to excise HIV proviral DNA...that leverages CRISPR’s evolutionary history as a viral defense system in bacteria...[It] utilizes an adeno-associated virus (AAV) to deliver a one-time treatment intended to functionally cure HIV infections. The investigational program employs CRISPR-Cas9 and two guide RNAs which target three sites within the HIV genome, thereby excising large portions of the HIV genome and minimizing potential viral escape.”

(Source: Excision BioTherapeutics, Inc, [News Release](#), 9/15/21) 💧

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2021

Sept. 22. **11th Annual Symposium on Red Cell Genotyping 2021: The New Normal, Bethesda, MD (Hybrid)**. For more information click [here](#) or contact [Natasha Leon](#).

Sept. 23. **U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) Meeting (Virtual)**. More information available [here](#).

Sept. 23. **NIH Clinical Center Department of Transfusion Medicine and The American Red Cross 40th Annual Immunohematology and Blood Transfusion Symposium (Virtual)**. More information available [here](#).

Sept 27-30. **Advanced Medical Technology Association (AdvaMed) MedTech Conference, Washington D.C., and Minneapolis Minn. (Hybrid)**. Registration is [open](#).

Oct. 17-19. **AABB Annual Meeting (Virtual)**. Registration is [open](#).

Nov. 3-4. **The Biomedical Advanced Research and Development Authority (BARDA) Industry Day (Virtual)**. More details available [here](#).

Nov. 4. **U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee Meeting (Virtual)**. More information available [here](#).

Dec. 6-8. **American Association of Tissue Banks (AATB) Annual Meeting (Virtual)**. Registration is [open](#).

2022

Mar. 7-10. **ABC Annual Meeting, Washington, D.C.** Additional details coming [soon](#).

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** Additional details coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Chief Clinical Officer. The Central California Blood Center seeks ideal candidates for new position of Chief Clinical Officer (CCO). Looking for an exceptional blood banking/transfusion medicine leader who can successfully navigate the ever-changing health care provider and blood industry landscapes to provide ever increasing value to our clients. The CCO will provide clinical, scientific, and technical expertise, supporting our senior management team, for our innovative and independent community blood center. The CCO will report to the President and CEO and oversee blood donor services, blood component manufacturing, donor testing lab, R&D programs, IRL, donor services, and IT departments. The CCO will shape and guide our team of high-achieving department directors to consistently exceed standards and goals for cGMP, productivity, and customer service. The CCO will continue our trend of bringing innovation to our successful independent community blood center. The ideal candidate will enhance our stature in blood banking, cellular therapies, and other mission compatible partnerships with biotech. We envision the successful candidate will have opportunities to advance towards future CMO and/or CEO roles in the mid-decade. MS, SBB, PhD or MD preferred. Strong and progressive blood industry leadership experience required. Please send inquiries to lchristiansen@donateblood.org.

Immunohematology Technician. Join our team! LifeServe Blood Center currently has one full-time opening for a Medical Technician at our Omaha, NE location. This laboratory reference position serves hospital patients across Iowa, Nebraska, and South Dakota. Testing includes basic blood banking and complex antibody identification. Primary Responsibilities for this Position Include: Accepts, verifies, processes, and tests incoming samples; Performs various testing procedures, including immunohematology, on donor and patient blood products; Performs quality control, equipment maintenance and calibration; Utilizes computer system to obtain necessary data and to record test results; and Participates in the ongoing monitoring for each testing process to identify errors or potential problems. Education and/or Experience: MT/MLS or MLT from American Society for Clinical Pathology or equivalent; Bachelor's degree in medical technology or chemical, physical, or biological science or related scientific field from an accredited college or university or an equivalent combination of education, certification, training and or experience; and Meet current CLIA or ABB requirements for testing personnel. Interested applicants should visit our website: <https://www.lifeservebloodcenter.org/about-us/join-our-team/>. LifeServe Blood Center is fully committed to

equal employment opportunity. All applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identification, genetic information, marital status, pregnancy, disability, veteran status, or any other legally protected status.

Cord Blood Operations Manager. LifeSouth Community Blood Centers is currently seeking an individual to join our team as a Cord Blood Operations Manager in Gainesville, FL. This position oversees all Cord Blood processing operations, including assessment, record review, processing, long-term storage, and shipment/distribution of cord blood and cellular manufacturing operations. Applicants should apply here: <https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2203?c=lifesouth>.

Donor Testing Laboratory Director. The National Blood Testing Cooperative (NBTC) and LifeSouth Community Blood Centers is currently seeking a skilled individual for the Donor Testing Laboratory Director position in our Donor Testing Laboratory in Stone Mountain, GA. This position is responsible for the strategic planning, development, organization, coordination, management, and daily oversight of all activities associated with a blood testing laboratory. This position will also ensure the laboratory performs in accordance with all regulatory requirements and will possess the oversight and responsibility of all standard operating procedures (SOPs) within the lab. Applicants should apply here: <https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2241?c=lifesouth>.

Donor Testing Manager. LifeSouth Community Blood Centers is currently seeking a skilled individual for the Donor Testing Manager position in our Donor Testing Laboratory in Stone Mountain, GA. This position is responsible for providing management and oversight of assigned laboratory departments and staff. Applicants should apply here: <https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2240?c=lifesouth>.

Regional Donor Services Manager. Lifeline Blood Services, sole provider of blood products to twenty counties in West Tennessee, is seeking an experienced manager to oversee the regional operations of our fixed site blood centers. This position will be located in Dyersburg, TN and will be required to travel in between fixed sites to regularly monitor the operations to ensure compliance of

(continued on page 10)



POSITIONS (continued from page 9)

company polices, FDA, AABB, State, and other industry guidelines and oversee new site renovations as needed. The successful candidate will also proactively manage phlebotomy staff to achieve high performance by effectively utilizing feedback, coaching, and performance reviews while scheduling phlebotomy staff to ensure smooth workflow to meet established turnaround times. The Regional Donor Services Manager will create and sustain an environment conducive to an engaged and high performing team to achieve a positive donor experience. As a member of the leadership team, the Manager will model Lifeline's mission and values, integrating them into their daily routine. Associate's degree or comparable experience in management required. Bachelor's degree preferred. One to two years of administrative/management experience required, three plus years preferred. Lifeline offers a competitive beginning salary and generous benefits package, including medical, dental, and vision insurances, life insurance, paid time off, extended illness benefit, discount club membership, 401(k) with employer match, and tuition reimbursement. Click [HERE](#) to apply. 💧